Valuation: KDventures AB

Market Cap 170M 17.67M 15.45M 14.2M 13.23M 25.1M 1.68B 25.48M 66.25M 827M 66.33M 64.9M 2.85B P/E 2024
-31.7x
P/E 2025 -0.61x
Enterprise Value 148M 15.31M 13.38M 12.3M 11.46M 21.74M 1.46B 22.07M 57.39M 716M 57.45M 56.22M 2.47B EV / Sales 2024
118x
EV / Sales 2025 56.8x
Free-Float
65.1%
Yield 2024 *
-
Yield 2025 -
5 years 0
Extreme 0
0.26
10 years 0
Extreme 0
0.61
Manager TitleAgeSince
Chief Executive Officer 61 31/05/2017
Director of Finance/CFO 58 30/09/2022
Chief Investment Officer - -
Director TitleAgeSince
Director/Board Member 33 27/11/2017
Director/Board Member 57 18/02/2021
Chairman 50 17/12/2024
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 17.67M
+3.49%+1.36%-29.04%-11.15% 166B
+5.04%+2.73%-5.88%-4.24% 106B
+2.80%+3.63%+0.09%+55.53% 57.69B
-1.37%-0.89%+54.58%+57.19% 53.78B
+3.39%+1.39%-10.26%-39.27% 43.56B
+3.50%+11.11% - - 36.52B
+3.47%+1.58%-14.08%-44.37% 27.49B
+0.20%+4.24%+64.56%-2.99% 25.84B
+2.78%+1.17%-8.15%-0.33% 21.27B
Average +0.92%+4.67%+6.48%+1.30% 59.87B
Weighted average by Cap. +0.13%+3.80%-3.68%+1.91%

Financials

2024 2025
Net sales 1.84M 191K 167K 153K 143K 271K 18.14M 275K 715K 8.92M 715K 700K 30.73M 1.67M 173K 151K 139K 130K 246K 16.5M 250K 650K 8.11M 650K 636K 27.94M
Net income -8.1M -840K -734K -675K -629K -1.19M -79.97M -1.21M -3.15M -39.31M -3.15M -3.09M -135M -194M -20.1M -17.57M -16.15M -15.05M -28.55M -1.91B -28.98M -75.36M -941M -75.44M -73.82M -3.24B
Net Debt -39.9M -4.14M -3.62M -3.32M -3.1M -5.88M -394M -5.96M -15.51M -194M -15.53M -15.19M -667M -22.8M -2.36M -2.07M -1.9M -1.77M -3.36M -225M -3.41M -8.86M -111M -8.87M -8.68M -381M
Logo KDventures AB
Karolinska Development AB is a Sweden-based investment company. The Company provides capital to biotechnology firms, as well as develops and commercializes biotechnological products. Its activities are involved in a range of areas: oncology, infections and wound healing, women’s health, cardiovascular and hematology, medical equipment, diagnostics, pharmaceutical formulation, as well as implants, among others. The Company’s pharmaceuticals portfolio comprises: AXL1717 for non-small-cell lung carcinoma (NSCLC), APR-246 for ovarian cancer, Sevuparin for malaria, SHACT for pain relief at hysteroscopy and intrauterine device (IUD) insertion, and PC-mAB for acute coronary syndrome (ACS), among others. Furthermore, the Company controls a number of subsidiaries, such as Avaris AB, HBV Thernostica AB, KD Incentive AB, KDev Oncology AB and Limone AB.
Employees
7

Annual profits - Rate of surprise